


Supplemental Figure



Supplemental Table. Prophylaxis of GVHD using mycophenolate mofetil and incidence of GVHD in children undergoing hematopoietic stem cell transplant.

| References (published year) | Patient (N) | Age year (median) | Sex M/F | Diagnosis Malignant Non-malignant | Combined immunosuppressant (n) | Stem cell source (n) | HLA match (n) | Acute GVHD II-IV | III-IV | Chronic GVHD |
|---|----------------|----------------------|------------|---|---|---|--|---------------------|--------|-------------------------------|
| Chen H, et al. (2003) ²⁵ | 6 | 9–15 (13.5) | 5/1 | 6 0 | CsA + MTX + Basiliximab (6) | R-BM (6) | 5/6 (1), 4/6 (4), 3/6 (1) | 0% | 0% | 100% |
| Osunkwo I, et al. (2004) ¹³ | 34 | 0.5–21 (7) | 24/10 | 22 12 | TAC (34) | R-BM (6) R-PBSC (9) CB (22) | 6/6 (5), 5/6 (1) 6/6 (6) | 45% | 34% | 38% |
| Burroughs LM, et al. (2007) ²⁴ | 12 | 0.5–12.8 (1.5) | 8/4 | 0 12 | CsA (12) | R-BM (4) UR-BM (3) UR-PBSC (4) R-CB (1) | 10/10 (4) 10/10 (3) 10/10 (4) 10/10 (1) | 67% | 8% | 58% |
| Bhatia M, et al. (2010) ¹⁵ | 38 | 0.33–16 (8) | 20/18 | 21 17 | TAC (38) | R-BM (6) UR-BM (1) R-PBSC (10) CB (21) | 6/6 (6) 8/10 (1) 6/6 (7), 5/6 (3) | 54% | 42% | 34% |
| Styczynski J, et al. (2011) ¹⁶ | 12 | 2–20 (16) | 6/6 | 7 5 | TAC + Alemtuzumab (12) | UR-BM (1) R-PBSC (2) UR-PBSC (7) CB (2) | 10/10 (1) 6/6 (1), 5/6 (1) 10/10 (1), 9/10 (3), 8/10 (3) | 42% | 25% | 9% |
| Windreich RM, et al. (2016) ²⁶ | 19 | 0.9–21 (8.4) | 9/10 | 17 2 | CsA (19) | R-BM (7) UR-BM (6) CB (6) | 10/10 (7) 10/10 (6) 8/8 (2), 7/8 (3), 6/8 (1) | 33% | 22% | 13% |
| Militano O, et al. (2018) ²⁷ | 35 | 0.1–23 (12.5) | 26/9 | 25 10 | TAC (35) | R-BM/PBSC (14) UR-BM (11) R-CB (2) UR-CB (8) | 6/6 (14) 10/10 (7), 9/10 (4) 6/6 (2) 5/6 (8) | 22.8%* | 5.7%* | Limited 12%* Extended 23%* |
| This report | 35 | 0–15 (8) | 24/11 | 14 21 | TAC (18), TAC + MTX (11), CsA (1), ATG/ALG (2), Steroid (2) | UR-BM CB N/A (21) (6) (8) | 6/6 (11), 5/6 (10) | 29% | 9% | 16% |

Abbreviations: TAC, tacrolimus; CsA, Cyclosporin A; MTX, methotrexate; ATG, antithymocyte globulin; ALG, anti-lymphocyte globulin; R, related; UR, unrelated; BM, bone marrow; CB, cord blood; PBSC, peripheral blood stem cell; N/A, not available.

*Cumulative probabilities were estimated by the Kaplan–Meier method.